Nifty
Sensex
:
:
16106.55
53952.50
-108.15 (-0.67%)
-336.11 (-0.62%)

Pharmaceuticals & Drugs - Global

Rating :
37/99

BSE: 530549 | NSE: SHILPAMED

409.95
23-May-2022
  • Open
  • High
  • Low
  • Previous Close
  •  421.50
  •  421.50
  •  408.20
  •  421.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  110163
  •  452.65
  •  670.40
  •  380.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,561.48
  • 91.93
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,282.47
  • 0.27%
  • 1.98

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.01%
  • 12.43%
  • 20.12%
  • FII
  • DII
  • Others
  • 14.41%
  • 1.01%
  • 2.02%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.97
  • 2.95
  • 7.11

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.89
  • 1.22
  • 2.20

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.75
  • 5.63
  • 7.52

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 33.58
  • 27.43
  • 24.57

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.08
  • 3.03
  • 2.52

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.56
  • 20.48
  • 20.26

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Net Sales
340.59
208.03
63.72%
272.30
191.25
42.38%
295.27
278.94
5.85%
237.36
222.87
6.50%
Expenses
266.87
181.82
46.78%
227.21
170.28
33.43%
242.11
210.25
15.15%
205.48
157.11
30.79%
EBITDA
73.73
26.21
181.30%
45.09
20.97
115.02%
53.16
68.68
-22.60%
31.88
65.75
-51.51%
EBIDTM
21.65%
12.60%
16.56%
10.96%
18.00%
24.62%
13.43%
29.50%
Other Income
5.49
6.91
-20.55%
5.48
8.61
-36.35%
1.28
9.20
-86.09%
1.99
5.48
-63.69%
Interest
9.35
9.12
2.52%
9.92
4.80
106.67%
11.58
3.95
193.16%
10.32
4.00
158.00%
Depreciation
22.34
15.23
46.68%
20.65
13.72
50.51%
19.18
12.70
51.02%
17.63
12.33
42.98%
PBT
47.41
8.76
441.21%
20.00
11.05
81.00%
32.59
61.23
-46.77%
5.92
115.74
-94.89%
Tax
16.86
0.80
2,007.50%
9.71
2.92
232.53%
11.56
15.99
-27.70%
3.56
29.14
-87.78%
PAT
30.55
7.96
283.79%
10.29
8.14
26.41%
21.03
45.24
-53.51%
2.36
86.60
-97.27%
PATM
8.97%
3.83%
3.78%
4.25%
7.12%
16.22%
1.00%
38.86%
EPS
3.40
0.96
254.17%
1.10
0.94
17.02%
2.45
5.57
-56.01%
0.19
10.59
-98.21%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
1,145.52
901.13
907.91
733.39
788.83
779.16
716.43
613.80
571.38
371.32
318.18
Net Sales Growth
27.13%
-0.75%
23.80%
-7.03%
1.24%
8.76%
16.72%
7.42%
53.88%
16.70%
 
Cost Of Goods Sold
383.22
270.73
277.73
257.03
355.87
371.81
366.19
323.16
313.26
213.95
183.22
Gross Profit
762.30
630.40
630.18
476.36
432.95
407.36
350.25
290.63
258.12
157.38
134.96
GP Margin
66.55%
69.96%
69.41%
64.95%
54.89%
52.28%
48.89%
47.35%
45.17%
42.38%
42.42%
Total Expenditure
941.67
729.42
693.39
579.39
637.60
617.55
556.44
487.38
455.40
301.63
257.08
Power & Fuel Cost
-
40.25
38.76
33.57
28.86
26.30
21.90
19.29
17.37
10.67
9.38
% Of Sales
-
4.47%
4.27%
4.58%
3.66%
3.38%
3.06%
3.14%
3.04%
2.87%
2.95%
Employee Cost
-
235.31
196.59
176.40
149.35
127.87
90.09
82.30
67.83
42.56
33.68
% Of Sales
-
26.11%
21.65%
24.05%
18.93%
16.41%
12.57%
13.41%
11.87%
11.46%
10.59%
Manufacturing Exp.
-
88.99
79.19
61.23
59.96
52.55
45.35
36.55
27.44
16.92
12.89
% Of Sales
-
9.88%
8.72%
8.35%
7.60%
6.74%
6.33%
5.95%
4.80%
4.56%
4.05%
General & Admin Exp.
-
47.67
70.26
27.20
22.50
16.95
14.11
10.64
9.53
9.51
7.87
% Of Sales
-
5.29%
7.74%
3.71%
2.85%
2.18%
1.97%
1.73%
1.67%
2.56%
2.47%
Selling & Distn. Exp.
-
20.79
10.40
6.72
6.37
4.75
7.27
5.99
7.29
4.43
3.19
% Of Sales
-
2.31%
1.15%
0.92%
0.81%
0.61%
1.01%
0.98%
1.28%
1.19%
1.00%
Miscellaneous Exp.
-
25.68
20.47
17.23
14.68
17.32
11.54
9.45
12.68
3.59
3.19
% Of Sales
-
2.85%
2.25%
2.35%
1.86%
2.22%
1.61%
1.54%
2.22%
0.97%
2.16%
EBITDA
203.86
171.71
214.52
154.00
151.23
161.61
159.99
126.42
115.98
69.69
61.10
EBITDA Margin
17.80%
19.05%
23.63%
21.00%
19.17%
20.74%
22.33%
20.60%
20.30%
18.77%
19.20%
Other Income
14.24
40.09
22.22
15.56
32.62
29.34
11.36
6.93
9.12
5.01
8.28
Interest
41.17
21.87
4.56
3.68
2.66
3.13
3.93
4.05
3.52
2.27
2.31
Depreciation
79.80
53.98
43.78
42.06
37.22
30.64
23.14
21.41
23.22
15.34
14.36
PBT
105.92
135.95
188.40
123.82
143.96
157.17
144.28
107.89
98.35
57.10
52.71
Tax
41.69
48.85
33.49
26.18
33.91
42.04
35.62
35.22
20.30
9.53
12.22
Tax Rate
39.36%
24.82%
17.78%
18.22%
23.56%
27.54%
25.11%
32.66%
21.27%
16.72%
22.91%
PAT
64.23
149.52
156.50
120.28
112.43
113.71
109.84
73.69
75.67
47.35
41.23
PAT before Minority Interest
64.30
147.94
154.91
117.52
110.05
110.59
106.24
72.62
75.15
47.47
41.11
Minority Interest
0.07
1.58
1.59
2.76
2.38
3.12
3.60
1.07
0.52
-0.12
0.12
PAT Margin
5.61%
16.59%
17.24%
16.40%
14.25%
14.59%
15.33%
12.01%
13.24%
12.75%
12.96%
PAT Growth
-56.58%
-4.46%
30.11%
6.98%
-1.13%
3.52%
49.06%
-2.62%
59.81%
14.84%
 
EPS
7.40
17.23
18.03
13.86
12.95
13.10
12.65
8.49
8.72
5.46
4.75

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
1,478.67
1,329.36
1,197.58
1,085.03
986.90
639.26
546.94
396.45
320.42
275.98
Share Capital
8.15
8.15
8.15
8.15
8.01
7.71
7.71
7.36
4.90
4.90
Total Reserves
1,470.51
1,321.21
1,189.43
1,076.88
978.88
631.55
539.23
389.09
315.52
271.07
Non-Current Liabilities
567.90
256.94
166.62
153.48
251.26
67.23
154.15
104.53
98.51
31.13
Secured Loans
480.12
164.48
80.39
67.09
141.20
0.03
71.03
37.43
70.47
5.07
Unsecured Loans
0.35
0.53
0.70
1.03
1.30
0.00
31.30
30.05
0.00
0.00
Long Term Provisions
15.48
26.17
21.77
20.32
16.89
13.96
11.75
9.93
6.92
6.34
Current Liabilities
602.16
410.82
253.44
265.84
236.90
222.07
189.06
166.84
123.77
121.14
Trade Payables
72.15
92.55
80.72
103.74
111.86
106.48
75.50
92.98
51.26
56.72
Other Current Liabilities
275.30
142.10
81.62
59.59
28.03
36.49
49.32
38.23
23.38
20.34
Short Term Borrowings
243.40
165.27
86.58
98.12
92.41
74.10
58.47
30.27
45.07
41.24
Short Term Provisions
11.31
10.89
4.52
4.39
4.60
5.00
5.77
5.37
4.06
2.83
Total Liabilities
2,637.56
1,989.21
1,610.02
1,499.13
1,472.22
930.89
904.54
677.83
551.42
433.11
Net Block
1,110.53
650.44
558.01
534.20
491.93
393.41
316.06
294.42
180.67
166.61
Gross Block
1,421.35
986.42
853.16
793.24
704.89
582.20
476.34
448.38
300.89
271.30
Accumulated Depreciation
310.81
335.98
295.15
259.04
212.96
188.79
160.28
153.96
120.22
104.70
Non Current Assets
1,719.50
1,365.35
1,064.96
827.16
742.33
576.68
576.77
443.89
339.18
244.95
Capital Work in Progress
541.29
666.25
429.12
209.85
140.51
91.90
221.62
111.03
129.15
57.71
Non Current Investment
21.22
10.45
2.25
20.79
27.99
34.15
0.19
0.21
0.14
0.11
Long Term Loans & Adv.
43.35
32.42
48.75
37.47
77.09
51.86
38.74
38.18
28.82
20.17
Other Non Current Assets
3.11
5.78
26.84
24.86
4.80
5.36
0.16
0.06
0.40
0.34
Current Assets
918.05
623.85
545.06
671.97
729.88
354.21
327.61
233.74
211.99
187.87
Current Investments
0.00
0.00
0.00
119.54
224.62
59.63
65.35
10.14
50.28
68.02
Inventories
316.84
226.43
187.67
188.71
190.00
134.23
130.78
123.25
74.33
67.32
Sundry Debtors
222.69
246.79
203.73
220.27
170.93
125.43
81.37
67.96
41.79
40.53
Cash & Bank
123.11
44.56
94.54
73.83
100.39
11.03
18.42
9.19
16.87
2.27
Other Current Assets
255.42
76.81
45.04
26.08
43.95
23.90
31.69
23.20
28.72
9.72
Short Term Loans & Adv.
74.01
29.25
14.08
43.54
21.95
8.90
4.91
3.23
2.86
3.01
Net Current Assets
315.89
213.04
291.62
406.13
492.98
132.14
138.55
66.90
88.22
66.73
Total Assets
2,637.55
1,989.20
1,610.02
1,499.13
1,472.21
930.89
904.54
677.83
551.42
433.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
47.07
124.38
146.78
44.92
37.48
128.70
68.81
70.04
43.64
56.73
PBT
196.79
188.40
143.70
136.77
146.49
140.36
107.84
95.45
57.00
53.51
Adjustment
4.17
41.32
20.44
18.83
17.19
20.61
26.46
19.62
11.52
10.19
Changes in Working Capital
-106.29
-63.15
18.71
-69.66
-92.61
-2.70
-40.11
-23.44
-13.90
0.77
Cash after chg. in Working capital
94.67
166.57
182.85
85.94
71.08
158.27
94.19
91.62
54.62
64.46
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-47.60
-42.20
-36.07
-41.02
-33.60
-29.56
-25.38
-21.58
-10.98
-7.73
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-404.28
-289.52
-196.16
-8.76
-262.23
-109.20
-195.18
-48.93
-95.21
-152.31
Net Fixed Assets
-272.02
-4.28
-256.96
-136.75
-172.23
-92.14
-78.46
-61.02
-83.52
-79.20
Net Investments
-125.84
-4.44
141.85
95.51
-172.72
-14.09
-64.38
12.08
13.84
-73.05
Others
-6.42
-280.80
-81.05
32.48
82.72
-2.97
-52.34
0.01
-25.53
-0.06
Cash from Financing Activity
436.37
175.50
10.06
-60.91
312.70
-19.65
135.05
-28.34
66.31
10.02
Net Cash Inflow / Outflow
79.17
10.36
-39.32
-24.75
87.95
-0.15
8.68
-7.23
14.74
-85.56
Opening Cash & Equivalents
44.31
34.13
73.83
99.97
7.05
3.61
9.19
16.87
2.27
87.83
Closing Cash & Equivalent
123.34
44.31
34.36
73.83
99.97
6.43
18.42
9.19
16.87
2.27

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
181.37
163.06
146.89
133.09
123.17
82.91
70.92
107.72
43.52
74.94
ROA
6.39%
8.61%
7.56%
7.41%
9.20%
11.58%
9.18%
12.23%
9.64%
10.66%
ROE
10.54%
12.26%
10.30%
10.62%
13.60%
17.92%
15.40%
20.98%
15.93%
16.63%
ROCE
10.82%
12.41%
11.05%
11.71%
15.91%
19.90%
17.90%
20.48%
15.04%
18.02%
Fixed Asset Turnover
0.75
0.99
0.89
1.06
1.22
1.36
1.34
1.54
1.32
1.28
Receivable days
95.08
90.56
105.51
90.20
69.00
52.26
43.99
34.62
39.70
45.47
Inventory Days
110.03
83.24
93.66
87.32
75.49
66.97
74.84
62.33
68.31
62.38
Payable days
111.02
47.69
58.00
61.51
60.89
60.10
62.86
57.06
63.94
59.10
Cash Conversion Cycle
94.09
126.11
141.17
116.00
83.61
59.13
55.97
39.90
44.07
48.76
Total Debt/Equity
0.57
0.29
0.16
0.18
0.24
0.14
0.34
0.30
0.41
0.22
Interest Cover
10.00
42.34
40.09
55.10
49.69
37.07
27.63
28.09
26.13
24.13

News Update:


  • USFDA inspects Shilpa Medicare’s Analytical Services Division in Telangana
    2nd May 2022, 16:30 PM

    The inspection has been closed with four observations, which are related to improvements in existing procedures and are addressable

    Read More
  • Shilpa Medicare gets NoC from RCGM for Biosimilar Aflibercept
    26th Apr 2022, 10:49 AM

    The product is a biosimilar version of EYLEA of Regeneron for which currently there is no other biosimilar version on the Indian market

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.